News & Articles

Find out how to rapidly test for multiple disease-causing microorganisms with syndromic panel-based testing

EpiMOGRIFY supports the development of scalable off-the-shelf cell therapies for diseases with a high unmet clinical need

Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season

The Phase II clinical trial, which will use cutting-edge CRISPR genetic engineering, has already begun enrolling patients

The addition of COVID-19 antibody tests to the portfolio aims to further support the pandemic response on multiple fronts

Join us Thursday, October 22, to explore the applications and benefits of ambient ionization for biomedical research and its future potential for pharma and food industries

Access SARS-CoV-2 IgG assay shows excellent agreement with the Genscript Surrogate Virus Neutralization Test

Fluidigm COVID-19 campus safeguard program improves availability of non-invasive, saliva-based SARS-CoV-2 tests for higher education institutions

Researchers have made a significant COVID-19 drug target discovery using Thermo Fisher Scientific CryoEM technology

We speak with Dr. Ed Emmott, founder of The Emmott Lab & COVID-19 Mass Spec Coalition member, about his latest research into the disease

Affimer-based research assay launched alongside performance data published by Bruker

Early surgical treatment of leg ulcers caused by varicose veins improves healing and reduces the risk of the condition coming back

CE mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology

Menu of test solutions for infectious diseases – which already includes COVID-19 – to be expanded, especially in the U.S.

The Direct assay is validated on a wide range of specimen types, and can be run in parallel with the Simplexa Flu A/B & RSV Direct Gen II assay

cPass is first commercially available product to rapidly detect neutralizing antibodies capable of eliminating virus

The new line aims to provide unmatched sensitivity, resolution, speed, and flexibility of colors

Emergency scans captured images of the top of the lungs where a fluffiness known as ‘ground glass opacification’ allowed COVID-19 to be diagnosed

AstraZeneca anticipates entering clinical development in 2021

The technology is said to be superior at identifying cell types in human blood, providing faster and more reliable assessments for clinical decision making

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus

The partnership aims to co-market exosome technology as well as the joint development of new exosome based products

The collaboration aims to define threshold for neutralizing antibody sufficient to confer immunity

Access Anti-SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, aims to provide accurate results in less than 15 minutes

Agreements with AstraZeneca and the University of Nebraska Medical Center showcase new workflows to improve the throughput, robustness and standardization of clinical biomarker analysis